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Abstract 
As the COVID-19 pandemic spread worldwide, it has become clearer that prevalence of 
certain comorbidities in a given population could make it more vulnerable to serious outcomes 
of that disease, including fatality. Indeed, it might be insightful from a health policy perspective 
to identify clusters of populations in terms of the associations between their prevalent 
comorbidities and the observed COVID-19 specific death rates. In this study, we described a 
mixture of polynomial time series (MoPTS) model to simultaneously identify (a) three clusters 
of 86 U.S. cities in terms of their dynamic death rates, and (b) the different associations of 
those rates with 5 key comorbidities among the populations in the clusters. We also described 
an EM algorithm for efficient maximum likelihood estimation of the model parameters. 
Keywords: Mixture of regressions; EM; Death rate; Comorbidities; COVID-19. 
 
1. Introduction 
COVID-19 is an acute, respiratory disease due to novel coronavirus SARS-CoV-2, and 
similar to previous diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle 
East Respiratory Syndrome (MERS), it can lead to respiratory failure and death (CDCa, 2019). 
In the absence of any proven medical treatment for COVID-19, and in the face of acute shortage 
of critical care capacity, including ventilators, during peaks of incidence, as was witnessed in 
some countries such as Italy, it is of critical importance for any local administration to evaluate 
and stratify the risk levels in terms of its population comorbidities. 
As per current understanding (CDCb, 2020), individuals at-risk for severe illness from 
COVID-19 include people who are or have: (a) 65 years and older, (b) living in nursing home 
or long-term care facilities, (c) chronic lung disease or moderate to severe asthma, (d) serious 
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heart conditions, (e) immuno-compromised, (f) severe obesity, (g) diabetes, (h) chronic kidney 
disease undergoing dialysis, (i) hemoglobin disorders, and (j) liver disease.  
Early retrospective studies from China, Italy, and the U.S. revealed the prevalence of 
comorbidities in exacerbation of disease resulting in poor outcomes. Retrospective analysis of 
1,590 confirmed COVID-19 cases between December 11, 2019 and January 31, 2020 across 
31 provinces/autonomous regions in China indicated that 25.1% of the cases had at least one 
comorbidity. Specific prevalence included hypertension (16.9%), other cardiovascular diseases 
(53.7%) and diabetes (8.2%), whereas asthma, COPD, kidney diseases, immunodeficiency 
were below 1% (Guan et al., 2020). In a larger study across China, 72,314 patient records until 
February 11, 2020 were examined of which 44,672 were confirmed cases and further evaluated 
for comorbidities. (Feng et al., 2020) More than 50% of the records were missing data on 
comorbidities. Of available data on confirmed cases, comorbidities included hypertension 
(12.8%), diabetes (5.3%), and less than 4% for cardiovascular disorders, chronic respiratory 
disease, and cancers.  
The case-fatality ratio (CFR) is a useful indicator of survival prognosis among critically 
ill patients. During the peak of COVID-19 infections in China, the highest CFR was 14.8% 
among patients over age 80 years. CFR for patients with comorbid conditions was 10.5% for 
those with cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6% 
for hypertension and 5.6% for cancer, when compared to 0.9% for patients with no comorbid 
conditions. CFR for critical cases was 49% indicting the need to mitigate risks earlier in the 
infection. A meta-analysis of 6 COVID-19 studies indicated hypertension, diabetes, COPD, 
cardiovascular disease, and cerebrovascular disease as major risk factors for COVID-19 
patients (Wang et al., 2020). Another meta-analysis of pooled data from 8 studies in China, 
indicated a higher prevalence of hypertension and diabetes among patients with severe cases 
of COVID-19 disease (Yang et al., 2020). 
As the pandemic spread, Italy was next to experience large caseloads and CFR. COVID-
19 cases peaked in March to 3000-6500 new cases and 350-900 deaths daily. Comorbidities 
observed in deceased patients as of April 29, 2020 included hypertension (69.2%), diabetes 
(31.8%), cardiovascular conditions (22%), COPD (16.9%), obesity (11.6%) among others 
(Statista, 2020). In China and Italy, hypertension, diabetes, cardiovascular conditions, chronic 
respiratory disease accounted for the top comorbidities associated with severe outcomes (Chen 
et al., 2020). 
The first COVID-19 case in the U.S. was reported from Washington State on January 31, 
2020. Since then, the virus spread to the east coast and the rate of infections in New York 
exceeded every other state. As of April 30, 2020, New York had more than 30% of all the U.S. 
cases. A retrospective analysis of 5,700 records of patients hospitalized with COVID-19 in the 
New York City area revealed that while 6.1% of the patients had no comorbidities, and 6.3% 
had 1 comorbidity, as high as 88% had more than one comorbidity. This study further indicated 
that older patients, men, and those with pre-existing hypertension and/or diabetes were highly 
prevalent among those hospitalized for COVID-19 (Richardson et al., 2020). This pattern was 
similar to observations from China and Italy. In yet another observational cohort study at two 
New York hospitals, as of April 28, 2020, 39% of patients who were critically ill with COVID-
19 had died, and similar to studies in China and Italy, hypertension and cardiopulmonary 
comorbidities were found to be associated with increased mortality (Cummings et al., 2020). 
In this study, we modeled COVID-19 death rates and key comorbidities for 𝑁 = 86 U.S. 
cities. We used a mixture of regressions modeling approach to simultaneously identify the 
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clusters of cities in terms of their dynamic death rates, which had different associations with 
the prevalence of 5 key comorbidities among the populations in those clusters. We provided an 
EM algorithm for efficient maximum likelihood estimation of the model parameters. While the 
use of mixture of regressions models is well-known, [e.g., Jones and McLachlan (1992) and 
references in McLachlan and Peel (2000)], we think that the combination of finite mixtures, 
linear regression and polynomial modeling of time series makes our approach ideally suited 
for the present problem. We described our mixture of polynomial time series (MoPTS) model 
and the datasets in the next section, followed by the modeling results and discussion. 
 
2. Materials and Methods 
 
2a.  Datasets 
 
Comorbidities Data: The Centers for Disease Control and Prevention (CDC) has 
conducted each year, since 1984, the Behavioral Risk Factor Surveillance System (BRFSS), a 
cross-sectional representative telephone survey of U.S. adults (18 years or above) regarding 
their health conditions and behaviors. BRFSS now collects data from all 50 U.S. states and the 
districts of Columbia, Guam, and Puerto Rico. Both landline and cellular phone numbers are 
sampled in the survey and aggregated results are presented each year (CDCc, 2020). Health 
risk questions range from infectious diseases to chronic diseases and behaviors. The fixed core 
of the survey consists of a standard set of questions used by all states to include demographics 
and current health behaviors, e.g. tobacco use. In this study, we focus on 𝑝 = 5 comorbidities 
collected by BRFSS and reported at the county level: diabetes, obesity, coronary heart disease 
(CHD), hypertension, and chronic obstructive pulmonary disease (COPD).  
COVID-19 Data: Based on cumulative COVID-19 deaths data from the Johns Hopkins 
Coronavirus Resource Center (COVID-19 U.S. cases, 2020), we compiled time series data on 
daily deaths from the disease for the U.S. counties by their 5-digit FIPS code or county name. 
Since a single county may consist of multiple cities, we include the list of all city labels within 
each aggregate group to represent a greater metropolitan area. While we denote such 
metropolitan areas as “cities” for convenience, we identify them by their underlying county 
FIPS codes. In this study, we used the data for 𝑁 = 86 cities across the U.S. which had at least 
100 reported deaths from COVID-19 by May 31, 2020. We excluded New York City from our 
clustering as it is an outlier in terms of uniquely high incidence and extreme population 
heterogeneity, which could skew the model with its own singleton cluster. For each included 
city 𝑗	(𝑗 = 1,… , 𝑁), the daily number of deaths is given as a time series of 𝑛/ = 93 time points, 
over the period starting from 29 February, 2020, up to 31 May, 2020. For compatibility, the 
COVID-19-specific death rate was standardized as the number of deaths per 100,000 people 
using population data of the cities from the U.S. Census Bureau (U.S. Census Bureau). 
 
2b.  Mixture of Regressions Model 
 
In this study, we used a mixture of polynomial time series (MoPTS) model to cluster the 
above-mentioned (𝑁 = 86) cities in terms of their dynamic death rates into an optimal number 
(𝑔) of clusters (identified by the mixture model components 𝐶4, …	𝐶5), and investigate the 
differences among the estimated regression coefficients of 5 known comorbidities (given as 5 
static city-specific covariates) across those clusters.  
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Let 𝑌/7 be the random variable representing death rate at time 𝑡	(𝑡	 = 	1,… 𝑛/) for city 𝑗	(𝑗 = 1,… ,𝑁). It is assumed that the mean 𝜇:(𝑡) of each time series 𝑌/7 in the 𝑖th cluster 𝐶: 
follows 
 𝑌/7 − 𝜇:	(𝑡)	~::>	𝑁(0, 𝜎:A)	in 𝐶:	(𝑖 = 1,… , 𝑔) for all values of 𝑡	 = 	1, … 𝑛/ and 𝑗 = 1,… , 𝑁. 
Further, let 𝒙/ be a 𝑝-dimensional vector that describes static values of 𝑝 comorbidities for the 
city 𝑗 (𝑗 = 1, … ,𝑁). Also, let 𝑍/ is a component-indicator random variable to determine that 
city 𝑗 belongs to the component (or cluster) 𝐶: with probability 𝑃𝑟F𝑍/ 	= 𝑖G = 𝜋:	 such that 𝜋: > 0 and ∑ 𝜋:5:K4 = 1 for 𝑖 = 	1,… , 𝑔 and 𝑗 = 1,… ,𝑁. Thus, our mixture of regressions on 
time series modeled with order 𝐷 polynomial and covariates has the form: 
 𝑌/7 = 𝜶:N𝒙/ + ∑ 𝛽:>𝑡>Q>K4 + 𝜀/7; 		𝜀/7~	𝑁(0, 𝜎:A) with probability 𝜋:; 𝑖 = 1,… , 𝑔        (1) 
where 𝜶: = F𝛼:4, … , 𝛼:UGNare regression coefficients corresponding to the 𝑝 static covariates, 𝜷: = (𝛽:4, 𝛽:A, … , 𝛽:Q)N are coefficients corresponding to the polynomial time series.   
Let 𝒀/ = X𝑌/Y, 𝑌/4, … , 𝑌/Z[\N	arise from a 𝑔-component mixture of order 𝐷 polynomial 
time series with covariates model, denoted by MoPTS(𝐷, 𝑔), if it can be characterized by the 
conditional density function 𝑓F𝑦/7_𝒙/, 𝑍/ 	= 𝑖, 𝜽:G = 𝜙F𝑦/7; 𝜶:N𝒙/ + 𝜷:N𝒕Q, 𝜎:AG,			𝑗 = 1,… ,𝑁; 𝑡	 = 	1,… , 𝑛/,							(2) 
where 𝒕Q = (𝑡, 𝑡A, … , 𝑡Q)N and 𝜽: = (𝜶:N, 𝜷:N, 𝜎:A)N. 
Under the characterization (2), we can further characterize 𝒀/ via the joint density 
function 𝑓F𝒚/_𝒙/, 𝑍/ 	= 𝑖, 𝜽:G =e𝜋:f𝜙F𝑦/7; 𝜶:N𝒙/ + 𝜷:N𝒕Q, 𝜎:AGZ[7K4
5
:K4 ,			𝑗 = 1, … , 𝑁.										(3) 
Using the characterization (3), we can write the log-likelihood of an IID sample 𝒀4, … , 𝒀h as  
ℓ(𝜽) = elogme𝜋:f𝜙F𝑦/7; 𝜶:N𝒙/ + 𝜷:N𝒕Q, 𝜎:AGZ[7K4
5
:K4 nh/K4 ,																												(4) 
where the parameter 𝜽 = F𝜋4,… , 𝜋5p4, 𝜽4N, … , 𝜽5NGN is traditionally estimated by maximization 
of ℓ(𝜽) given by (4). However, in the absence of an analytical solution, we used an EM–type 
algorithm (Dempster et al., 1977; McLachlan and Peel 2000). Using log-likelihood criteria, we 
chose 𝐷 = 3 and 𝑔 = 3, i.e., our final fit produced a 3-component normal mixture regression 
model with the dependence of the mean on time modeled by a cubic polynomial.  
2c.  The observed information matrix  
In this section, the observed (Fisher) information matrix of MoPTS, defined as 𝐉(𝜽|𝒚) =− stℓ(𝜽)s𝜽s𝜽u, where ℓ(𝜽) = ∑ ℓ/(𝜽)h/K4 , ℓ/(𝚯) = logF∑ 𝜋: ∏ 𝜙F𝑦/7; 𝜶:N𝒙/ + 𝜷:N𝒕Q, 𝜎:AGZ[7K45:K4 G, is 
obtained.  
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It is well known that, under mild regularity conditions, the covariance matrix of the ML 
estimates 𝚯x  can be approximated by the inverse of 𝐉(𝚯|𝒚). Thus, following Basford et al. 
(1997), we approximated 𝐉(𝚯|𝒚) as 𝐉(𝜽|𝒚) ≈e𝒔{/𝒔{/Nh/K4 ,																																																																						(5) 
where 𝒔{/ = sℓ[(𝜽)s𝜽 |𝜽K𝜽x, and consider now the vector 𝒔{/ which is partitioned into components 
corresponding to all the parameters in 𝜽 as 
 𝒔{/ = X?̂?/, , … , ?̂?/,, 𝒔{/,𝜶N ,… , 𝒔{/,𝜶N , 𝒔{/,𝜷N , … , 𝒔{/,𝜷N , ?̂?/,t, … , ?̂?/,t\N, 
 
where its coordinate elements for 𝑖 = 1, … , 𝑔 are given by  
  
?̂?/, = 𝜙Z[F𝒚/_𝒙/, 𝜽:G − 𝜙Z[F𝒚/_𝒙/, 𝜽5G𝑓F𝒚/_𝒙/, 𝜽G ,					𝒔{/,𝚫𝒊 = 𝜋:𝐷𝚫𝒊 𝜙Z[F𝒚/_𝒙/, 𝜽:G𝑓F𝒚/_𝒙/, 𝜽G , 
 
where 𝑓F𝒚/_𝒙/, 𝜽G = ∑ 𝜋:𝜙Z[F𝒚/_𝒙/, 𝜽:G5:K4  and 𝚫: = 𝜶:, 𝜷: and 𝜎:A, for which 𝜙Z[F𝒚/_𝒙/, 𝜽:G = ∑ 𝜋: ∏ 𝜙F𝑦/7; 𝜶:N𝒙/ + 𝜷:N𝒕Q, 𝜎:AGZ[7K45:K4  and 𝐷𝚫𝒊 𝜙Z[F𝒚/_𝒙/, 𝜽:G =𝜕𝜙Z[F𝒚/_𝒙/, 𝜽:G 𝜕𝚫:⁄ . Thus, 𝐷𝜶 𝜙Z[F𝒚/_𝒙/, 𝜽:G =  1√2𝜋𝜎:Z[ 𝑠 exp −	12 𝑠 ; 𝐷𝜷 𝜙Z[F𝒚/_𝒙/, 𝜽:G =  1√2𝜋𝜎:Z[ 𝑠7 exp −	12 𝑠 ; 𝐷t 𝜙Z[F𝒚/_𝒙/, 𝜽:G =  1√2𝜋𝜎:Z[ 12 𝜎:AZ[pA 𝑠 −	𝑛/ exp −	12 𝑠 ; 
where 𝑠 = 4t ∑ F𝑦/7 − 𝜶:N𝒙/ − 𝜷:N𝒕QGAZ[7K4 , 𝑠 = 4t ∑ 𝒙/F𝑦/7 − 𝜶:N𝒙/ − 𝜷:N𝒕QGZ[7K4  and 𝑠7 =4t ∑ 𝒕QF𝑦/7 − 𝜶:N𝒙/ − 𝜷:N𝒕QGZ[7K4 . 
2d.  ML estimation  
In this section, we develop an efficient EM algorithm for maximum likelihood (ML) 
estimation of the parameters of the MoPTS model, using an incomplete-data framework. To 
compute this procedure, we use the following hierarchical representation:  𝑌/7_𝒙/, 𝑍/: = 1		 	𝑖𝑖𝑑~	 		𝑁F𝜶:N𝒙/ + 𝜷:N𝒕Q, 𝜎:AG,			𝑖 = 1,… , 𝑔.					 𝑃𝑟F𝑍/7 	= 𝑖G = 𝜋:	(𝑖	 = 	1,… , 𝑔; 	𝑗 = 1,… ,𝑁; 𝑡	 = 	1,… , 𝑛/),																			(6)	 
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Let 𝒚 = (𝒚4N, , … , 𝒚hN)N, 𝒙 = (𝒙4N, , … , 𝒙hN)N and 𝒛 = (𝒛4N,… , 𝒛hN)N for which 𝒛/ =(𝑧/4,… , 𝑧/5)N; 	𝑗 = 1, … , 𝑁, so considering the complete data 𝒚 = (𝒚N, 𝒙N, 𝒛N)N and using the 
hierarchical representation in (6) of the MoPTS(𝐷, g) model, the complete data likelihood, 
ignoring the constant term, is given by  
 𝒫(𝜽|𝒚) =eee𝐼[:]F𝑧/7G log𝜋: + log𝑓F𝑦/7_𝒙/, 𝑍/ 	= 𝑖, 𝜽:G¡Z[7K4
5
:K4
h
/K4=elog𝜋:ee𝐼[:]F𝑧/7GZ[7K4h/K4
5
:K4 −elog𝜎:ee𝐼[:]F𝑧/7G
Z[
7K4
h
/K4
5
:K4− 12e 1𝜎:Aee𝐼[:]F𝑧/7GF𝑦/7 − 𝜶:N𝒙/ − 𝜷:N𝒕QGAZ[7K4h/K4
5
:K4  
where 𝐼[:]F𝑧/7G is 1 if 𝑦/7 belongs to the ith component and zero otherwise, and 𝑓F⋅ _𝒙/, 𝑍/ 	= 𝑖, 𝜽:G was defined in (2). 
Starting from some initial value 𝜽(Y), the conditional expectation of (7), given the 
observed data, was computed using 𝜽(£) for 𝜽, can be written as 
𝑄F𝜽_𝜽(£)G =elog 𝜋𝑖ee𝛾/:7F𝜽(£)GZ[7K4h/K4
𝑔
𝑖=1 −elog 𝜎𝑖ee𝛾/:7F𝜽(£)G
Z[
7K4
h
/K4
𝑔
𝑖=1
− 12e 1𝜎:Aee𝛾/:7F𝜽(£)GF𝑦/7 − 𝜶:N𝒙/ − 𝜷:N𝒕QG2Z[7K4h/K4
𝑔
𝑖=1 ,			
where 𝛾/:7(𝜽) = 𝜋𝑖𝜙F𝑦/7; 𝜶:N𝒙/ + 𝜷:N𝒕Q, 𝜎:AG∑ 𝜋𝑖𝜙F𝑦/7; 𝜶¦N𝒙/ + 𝜷¦N𝒕Q, 𝜎¦AG𝑔𝑠=1 .																																											
The posterior probability is the conditional probability that 𝑦/7 belongs to the ith component 
given 𝒙/	and 𝒚/(7) for 𝑖	 = 	1, … , 𝑔; 	𝑗 = 1,… , 𝑁 and 𝑡	 = 	1,… , 𝑛/. To perform the M-step, 
under the restriction ∑ 𝜋:5:K4 = 1, by constructing the Lagrangian Λ(𝜽, 𝜆) = 𝑄F𝜽_𝜽(£)G +𝜆F∑ 𝜋:5:K4 − 1G, we maximize (8) in the EM algorithm by solving the equation corresponding 
to the first-order condition ∇Λ(𝜽, 𝜆) = 𝟎, where ∇ is the gradient operator, which yields the 
following updates 𝜋{:(£«4) = ∑ ∑ ¬[­F𝜽x(®)G¯[­°±[° h 	,																																																			(10) 𝜶²:(£«4) = ³∑ ∑ 𝛾/:7F𝜽x(£)G𝒙/𝒙/NZ[7K4h/K4 ´p4 ∑ ∑ 𝛾/:7F𝜽x(£)G𝒙/X𝑦/7 − 𝒕QN𝜷x:(£)\Z[7K4h/K4 	,						(11) 𝜷x:(£«4) = ³∑ ∑ 𝛾/:7F𝜽x(£)G𝒕Q𝒕QNZ[7K4h/K4 ´p4 ∑ ∑ 𝛾/:7F𝜽x(£)G𝒕QX𝑦/7 − 𝒙/N𝜶²:(£«4)\Z[7K4h/K4 	,										(12) 
(7) 
(8) 
(9) 
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𝜎{:A(£«4) = ∑ ∑ ¬[­F𝜽x(®)GX[­p𝒙[u𝜶²(®µ)p𝒕¶u𝜷x(®µ)\t¯[­°±[° ∑ ∑ ¬[­F𝜽x(®)G¯[­°±[° 	.																												(13) 
The steps of the above algorithm are iterated until a suitable convergence rule is satisfied, e.g., _ℓF𝜽x(£«4)G ℓF𝜽x(£)G· − 1_ ≤ 𝜀 for a pre-decided tolerance 𝜀. 
 
3. Results and Discussion 
Based on the log-likelihood model selection criteria, our optimal 3-component MoPTS 
model with the dependence of the mean death rate on time was modeled by a cubic polynomial. 
Thus, we identified 3 clusters of U.S. cities specified by the different associations between their 
death rates and comorbidities. Figure 1 depicts the time series of each cluster along with the 
fitted cubic polynomial models. The differences in the death rates (y-axes) across the 3 clusters 
can be noted. Table 1 lists the counties and states corresponding to these 86 cities, and their 
cluster memberships. Table 2 shows the parameter coefficients of the MoPTS (𝐷 = 3, 𝑔 = 3) 
model as estimated by the EM algorithm, along with the corresponding standard deviations. 
Cluster 1 contains 21 cities concentrated mostly in the northeastern part of the U.S. 
(Figure 2a) with death rates associated with diabetes (𝛼44) and hypertension (𝛼4¹). Cluster 2 
consists of 29 cities (Figure 2b) that are more spatially distributed than those in cluster 1, and 
has relatively weaker association with CHD (𝛼Aº), diabetes (𝛼A4) and COPD (𝛼A»). Cluster 3 
(Figure 2c), comprised of 36 cities, is the most geographically heterogeneous, which possibly 
explains why its association with the comorbidities hypertension (𝛼º¹) and COPD (𝛼º») are 
the weakest among the three clusters. Nonetheless, the results of our MoPTS model are in 
general agreement with the current understanding of the role of comorbidities in COVID-19 
outcomes (CDCb, 2020). 
While the geographical distribution of the clusters are no doubt represented by the 
populations therein and the underlying health and behavioral risk factors, environmental 
exposures, chronic conditions and comorbidities, it is important to avoid the risk of so-called 
ecological fallacy in attempting to infer individual disease outcomes based on data or results 
obtained at the level of large cities or counties. Indeed, the aim of our analysis is to provide 
insights into the existence of multiple patterns by which the current pandemic could affect the 
death rates in different metropolitan areas or counties in terms of their prevailing comorbidities. 
Such patterns could vary locally even within the same state. For instance, the disease dynamics 
as of 31 May 2020, at Allegheny county, which is located in western Pennsylvania and contains 
the city of Pittsburgh, was set apart (in cluster 3) from the other counties in the same state that 
lie more to the east and, indeed, share a different dynamic pattern (all of these are in cluster 2).  
In the future, we aim to study possible interactions between different comorbidities as 
well as potential pathways leading from such comorbidities to various COVID-19 outcomes 
that were observed in diverse populations globally. With further availability of electronic health 
records, clinical evaluation and other microdata derived from monitoring the progression of the 
disease, more precise inferences can be drawn. Towards this, we could extend our present 
approach to time series models such as due to Hajrajabi and Maleki (2019) and Zarrin et al. 
(2019), and also the flexible class of distributions introduced by Hoseinzadeh et al. (2019), 
Moravveji et al. (2019) and Maleki et al. (2019). 
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As the pandemic progresses, we will have better understanding of the complex interplay 
of different comorbidities – acting either singly or in combination – in COVID-19 disease 
progression, especially of those leading to severe outcomes. Naturally, population differences 
between diverse geographies and societies might make such associations hard to generalize. 
Yet, certain putative risk factors, such as Type 2 diabetes or CHD, may be common among 
populations around the world. Toward this end, healthcare systems may want to develop 
pandemic resiliency with targeted communications and policies that are aimed at patients 
grouped by low to high risk categories based on their health, lifestyles, and environments. Such 
risk stratification would enable healthcare systems to prepare for effectively treating critical 
cases of the disease and minimizing fatality during both this pandemic as well as those in the 
future based on the known prevalence of comorbidities within the populations they serve. 
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APPENDIX 
 
Table 1: Estimated parameters of the MoPTS (𝑫 = 𝟑,𝒈 = 𝟑) with standard deviations. 𝑪𝟏 Est. S.D. 𝑪𝟐 Est. S.D. 𝑪𝟑 Est. S.D. 𝝅𝟏 0.244186 4.235e-01 𝜋A 0.33721 3.683e-02 𝜋º 0.418604 5.012e-02 
a𝟏𝟏 2.09397 8.311e-02 aA4 0.54520 1.321e-01 aº4 –0.02475 1.074e-03 𝜶𝟏𝟐 –1.32063 3.242e-02 𝛼AA –0.13055 2.032e-02 𝛼ºA –0.03225 2.034e-02 𝜶𝟏𝟑 –2.66249 4.101e-01 𝛼Aº 0.65799 1.721e-02 𝛼ºº –0.02447 2.984e-03 𝜶𝟏𝟒 1.62983 3.422e-03 𝛼A¹ –0.14953 2.032e-03 𝛼º¹ 0.06790 3.352e-03 𝜶𝟏𝟓 –0.29323 3.012e-02 𝛼A» 0.52714 2.857e-02 𝛼º» 0.03763 2.405e-02 𝜷𝟏,𝟏 –1.85318 6.037e-02 𝛽A,4 –0.73512 9.063e-02 𝛽º,4 –0.08560 7.342e-03 𝜷𝟏,𝟐 0.14396 3.755e-02 𝛽A,A 0.048204 4.234e-03 𝛽º,A 0.00883 8.311e-03 𝜷𝟏,𝟑 –0.00136 4.937e-05 𝛽A,º –0.00039 9.043e-04 𝛽º,º –0.00006 1.003e-05 𝝈𝟏𝟐 574.38301 2.223e01 𝜎AA 75.21687 0.389e01 𝜎ºA 16.30303 0.232e01 
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Table 2: Three clusters of 86 U.S. cities identified by the 3 components of the MoPTS 
model. The county and the state (including District of Columbia) of each city are shown. 
Cluster 1 (21  members) Cluster 2 (29 members) Cluster 3 (36 members) 
Fairfield, Connecticut 
Hartford, Connecticut 
New Haven, Connecticut 
Dougherty, Georgia 
Jefferson, Louisiana 
Orleans, Louisiana 
Essex, Massachusetts 
Hampden, Massachusetts 
Middlesex, Massachusetts 
Norfolk, Massachusetts 
Plymouth, Massachusetts 
Suffolk, Massachusetts 
Macomb, Michigan 
Oakland, Michigan 
Wayne, Michigan 
Essex, New Jersey 
Hudson, New Jersey 
Mercer, New Jersey 
Passaic, New Jersey 
Union, New Jersey 
Westchester, New York 
Arapahoe, Colorado 
Denver, Colorado 
Weld, Colorado 
Washington, District of Columbia 
Cook, Illinois 
DuPage, Illinois 
Lake, Illinois 
Will, Illinois 
Lake, Indiana 
Marion, Indiana 
Caddo, Louisiana 
East Baton Rouge, Louisiana 
Baltimore City, Maryland  
Bristol, Massachusetts  
Worcester, Massachusetts 
Genesee, Michigan 
Hennepin, Minnesota 
St. Louis City, Missouri 
Camden, New Jersey 
Erie, New York 
Lucas, Ohio 
Mahoning, Ohio 
Berks, Pennsylvania  
Lackawanna, Pennsylvania 
Lehigh, Pennsylvania 
Northampton, Pennsylvania 
Philadelphia, Pennsylvania 
King, Washington 
Milwaukee, Wisconsin 
Jefferson, Alabama 
Mobile, Alabama 
Maricopa, Arizona 
Pima, Arizona 
Los Angeles, California 
Orange, California 
Riverside, California 
San Bernardino, California 
San Diego, California 
Santa Clara, California 
Adams, Colorado 
Jefferson, Colorado 
New Castle, Delaware 
Broward, Florida 
Lee, Florida 
Miami Dade, Florida 
Palm Beach, Florida 
DeKalb, Georgia 
Fulton, Georgia 
Kane, Illinois 
Polk, Iowa 
Jefferson, Kentucky 
Ramsey, Minnesota 
Clark, Nevada 
Hillsborough, New Hampshire 
Onondaga, New York 
Cuyahoga, Ohio 
Franklin, Ohio 
Hamilton, Ohio 
Summit, Ohio 
Allegheny, Pennsylvania 
Shelby, Tennessee 
Dallas, Texas 
Harris, Texas 
Tarrant, Texas 
Snohomish, Washington 
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Figure 1: Time series plots (grey) of 86 U.S. cities belonging to clusters 1 (a), 2 (b) and 3 
(c) based on 𝒈 = 𝟑 mixture components, superimposed with the fitted MoPTS model 
(red) for each city. The x-axis denotes time and y-axis COVID-19 death rate. The clusters 
show marked differences in their respective ranges of death rates (y-axes) over time.  
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Figure 2. Geographical distribution of the U.S. cities in clusters 1 (a), 2 (b), and 3 (c) based 
on MoPTS model. On a map, a bubble’s location shows the latitude and longitude of a 
city C, its size is proportional to the COVID-19-specific death rate at C as on May 31, 
2020, while its shading is proportional to the prevalence of the leading comorbidity in the 
cluster to which C belongs. 
